Rovartal

Rosuvastatin

Method of action: Inhibiting Hmg-Coa Reductase, Lipid Modifying Agents, Lipid-Lowering

Treatment option: Arteriosclerosis/Atherosclerosis, Heart Disease, Heterozygous Familial Hypercholesterolemia, Hyperlipidemia, Hyperlipoproteinemia, Hypertension, Hypertriglyceridemia, Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Dyslipidemia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rovartal

Property	Description
Active ingredient	Rosuvastatin Calcium
Form	Film-coated tablet (Oral)
Pharmacological class	HMG-CoA Reductase Inhibitor (Statin)
Common use	Reduction of high blood cholesterol
Origin	Synthetic compound

What Type of Medicine is Rovartal? Identity and Classification

Rovartal is a prescription-only, synthetic drug that belongs to the class of medications known as statins, which are formally classified as antihyperlipidemic agents. The medicine is designed for systemic action and is administered via the oral route as a single-ingredient, film-coated tablet. Rosuvastatin, the active compound, is a high-intensity statin due to its pronounced ability to lower low-density lipoprotein cholesterol (LDL-C) levels across its therapeutic range. The medication is associated with a predictable lipid-lowering profile in patients requiring significant cholesterol management.

Composition of Rovartal: The Role of Rosuvastatin

The effectiveness of Rovartal is due to its active ingredient, Rosuvastatin Calcium, a synthetic compound that works by specifically targeting the liver. This molecule is a competitive inhibitor of the β-Hydroxy-β-methylglutaryl-CoA reductase (HMG-CoA reductase) enzyme, the step in the liver responsible for the body’s endogenous cholesterol production. Rosuvastatin is known for its relatively long half-life, a key pharmacokinetic characteristic which allows for flexible, consistent dosing. The oral tablet formulation contains specific excipients to ensure the stable delivery of this high-potency active substance.

General Purpose of Rovartal: Addressing High Cholesterol

The general purpose of Rovartal is to manage and significantly reduce elevated levels of fats in the bloodstream, a condition known as hyperlipidemia. By inhibiting cholesterol production in the liver, the medication consequently promotes the clearance of “bad” LDL-C from the circulation. This action results in the ability to modify the lipid profile. A typical scenario for its use involves a patient with documented primary hypercholesterolemia who requires a robust intervention to achieve target cholesterol levels. Ultimately, this control over circulating lipids is crucial for achieving the primary goal of cardiovascular risk reduction.

Regulatory References

NIH StatPearls

What side effects are possible with Rovartal?

Possible side effects and safety information

The safety profile of Rovartal (Rosuvastatin) is documented in official regulatory classifications, which group adverse reactions by affected body system and frequency of occurrence. Frequencies are standardized as common, uncommon, rare, and very rare based on clinical trial data and post-marketing reports.

Frequency and System Classification

Common Adverse Reactions (may affect up to 1 in 10 people) typically involve the nervous system (e.g., headache, dizziness), the gastrointestinal tract (e.g., constipation, nausea, abdominal pain), and the musculoskeletal system (myalgia or muscle pain). Asthenia (weakness) and new-onset diabetes mellitus are also officially listed as common adverse effects.

System Organ Class	Common Adverse Reactions
Nervous System Disorders	Headache, Dizziness
Gastrointestinal Disorders	Constipation, Nausea, Abdominal pain
Musculoskeletal & Connective Tissue	Myalgia (Muscle pain)
Metabolism & Nutrition Disorders	New-onset Diabetes Mellitus

Uncommon effects include skin reactions like rash and pruritus. Rare effects involve more serious reactions such as pancreatitis, hepatitis, and jaundice.

Serious Safety Concerns and Specific Constraints

The most significant safety concerns officially highlighted involve the risk of rhabdomyolysis, a rare but serious muscle breakdown. Myopathy and, rarely, immune-mediated necrotizing myopathy (IMNM) have also been documented. Hepatobiliary reactions are considered serious, and the medicine is contraindicated in patients with active liver disease.

Safety notes specify patterns tied to exposure: Proteinuria may be observed at the start of treatment or following dose increase, while the risk of new-onset diabetes mellitus is associated with long-term use. Furthermore, regulatory information includes specific safety considerations for patients with severe renal or hepatic impairment and notes concerning use in Asian patients.

Overdose and Emergency Response

Overdose and when to seek help

Official Regulatory Information for Rovartal (Rosuvastatin Calcium)

Experience with specific acute Rosuvastatin overdose events is limited according to official regulatory documentation. The management of overdose is therefore primarily guided by the drug class's known risks and the potential for serious, dose-dependent effects.

Documented Manifestations and Serious Outcomes

Feature	Official Regulatory Statement
Documented Presentations	Specific clinical symptoms are not definitively documented. Findings reported in high-dose studies include transient elevations of liver transaminases and Creatine Kinase (CK) levels.
Serious Theoretical Outcome	The primary concern is the potential for rhabdomyolysis, a severe, dose-dependent muscle toxicity associated with statins, which necessitates careful monitoring.

Emergency Actions Mandated by Regulators

Feature	Official Regulatory Statement
When to Seek Help	Immediate medical attention must be sought for any suspected or confirmed overdose.
Antidote Availability	No specific antidote is known for Rosuvastatin overdose.
Supportive Management	Treatment is required to be symptomatic and supportive. Measures such as gastric lavage may be considered to limit absorption soon after ingestion.
Monitoring Requirements	Close monitoring of the patient's liver function and CK levels is required. The drug's high protein binding means hemodialysis is not expected to be effective for removal.

Therapeutic Uses of Rovartal

What Rovartal Treats: Main Uses and Benefits

Rovartal is generally used for managing conditions characterized by periods of heightened symptoms related to systemic imbalance, primarily through its use as a lipid-lowering agent. The main therapeutic area for the drug is applied in addressing elevated levels of low-density lipoprotein cholesterol (LDL-C), as well as addressing conditions such as hypertriglyceridemia and certain types of familial hypercholesterolemia in adults and certain pediatric patients.

This medication is considered relevant when supportive symptom management is appropriate in clinical settings that involve acute or unstable symptom patterns related to cardiovascular health. It may assist with maintaining functional stability in situations where patients experience conditions associated with acute or disruptive episodes such as myocardial infarction and stroke.

This medication assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms associated with systemic imbalance.

It supports general well-being during symptomatic phases and is commonly used to help with the long-term physiological burden linked to these conditions. It provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Rovartal is relevant for easing symptom clusters that may become intense or disruptive due to systemic imbalance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Rovartal? Official Regulatory Information

The eligibility for Rovartal (Rosuvastatin) is strictly defined by government regulatory authorities based on population status, pre-existing conditions, and risk factors.

Category	Official Eligibility Statement
Populations for whom use is allowed	Adults and pediatric patients with certain familial hypercholesterolemia conditions. Pediatric use is generally established for children aged 6 to 8 years and older, depending on the specific condition and regional regulatory label.
Populations for whom use is contraindicated	Patients with a known hypersensitivity to the medicine or any of its components. Use is strictly prohibited for those with active liver disease (including unexplained persistent elevation of hepatic transaminases) or severe renal impairment (creatinine clearance <30 mL/min).
Pregnancy and Lactation Status	Contraindicated in women who are pregnant or who may become pregnant (unless using effective contraception). Breastfeeding is not recommended during treatment.
Eligibility-Related Restrictions	The highest 40 mg dose is contraindicated in patients with predisposing factors for muscle toxicity, such as moderate renal impairment (CrCl <60 mL/min), inadequately treated hypothyroidism, or those of Asian descent.

Eligibility is also restricted for patients with existing myopathy or a history of hereditary muscular disorders. Rovartal is not recommended for use in children under 6 years of age, as safety and efficacy have not been established in this group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Rovartal (Rosuvastatin) identifies specific interaction patterns, primarily categorized by effects on drug exposure and risk reinforcement. These patterns establish constraints on co-administration with other substances.

Contraindicated Combinations

Co-administration is formally contraindicated with Ciclosporin and the combination of Sofosbuvir/Velpatasvir/Voxilaprevir. These combinations result in a significant increase in rosuvastatin plasma concentration, heightening the documented risk of myopathy.

Exposure Modification and Risk Reinforcement

Interactions often stem from inhibition of hepatic drug transporters, such as OATP1B1 and BCRP. Inhibitors of these transporters, including certain Protease Inhibitors (e.g., Lopinavir/Ritonavir), lead to increased rosuvastatin systemic exposure, necessitating dose adjustments or limitations.

Pharmacodynamic Reinforcement: The use of Rovartal with Fibrates (like Gemfibrozil) increases the documented risk of severe muscle toxicity, and co-administration should be avoided. Combining Rovartal with Coumarin Anticoagulants (e.g., Warfarin) requires specific monitoring, as this interaction prolongs the International Normalized Ratio (INR).
Timing Requirement: Aluminum and Magnesium Hydroxide Combination Antacids decrease rosuvastatin plasma concentration. Rovartal must be administered at least 2 hours after taking the antacid to maintain intended exposure.

Population-Specific Notes

Specific populations have officially documented interaction cautions. For instance, Asian Patients exhibit increased systemic exposure, and the use of the drug is contraindicated in patients with active liver disease or severe renal impairment.

Mechanism of Action

Molecular Blockade of Cholesterol Synthesis

The primary mechanism involves the highly specific, competitive inhibition of the HMG-CoA reductase (HMGCR) enzyme within liver cells (hepatocytes). This molecular action inhibits the rate-limiting step of the Mevalonate pathway, which is the body's major route for endogenous cholesterol production.

Enhanced Systemic Clearance of LDL-C

The resulting reduction in internal liver cholesterol triggers a compensatory feedback mechanism: the significant upregulation and deployment of Low-Density Lipoprotein (LDL) Receptors on the cell surface. This enhances the catabolism (systemic removal) of circulating LDL-C particles, producing the drug's core physiological effect: a reduction in plasma LDL-C levels.

Non-Lipid Modulation of Vascular Pathways

Beyond its main lipid action, the mechanism engages in pleiotropy by inhibiting intermediary products (isoprenoids) within the Mevalonate pathway. This secondary effect modulates small GTP-binding proteins, leading to the modulation of the functional status of the vascular endothelium and is associated with a reduction in systemic inflammatory markers.

Dosage and Administration Information

How to Use Rovartal: Official Administration Guidelines

Rovartal (rosuvastatin) is administered by the oral route as a film-coated tablet and is intended for chronic, long-term therapy. The tablet must be swallowed whole, and it may be taken once daily at any time of day, independent of meals.

Standard Dosing and Schedule

The standard adult initial dose is generally 10 mg or 20 mg once daily, although a 5 mg starting dose is available for patients requiring less intensive lipid reduction. The maximum recommended daily dose for general use is 40 mg, which is typically reserved for individuals who have not achieved their lipid goal on the 20 mg dose.

Any adjustment to the dosage, known as titration, should be made only after a minimum of two to four weeks of treatment at the current dose. If a dose is missed, the patient should not take an extra dose to compensate; treatment should resume with the next scheduled dose as usual.

Population-Specific Use

Specific considerations exist for certain patient populations. For patients with severe renal impairment who are not on hemodialysis, the starting dose is 5 mg and the daily dose must not exceed 10 mg. Additionally, a 5 mg starting dose is utilized for Asian patients due to the potential for increased systemic exposure.

Recent Clinical Evidence

Combination Strategy

Research has investigated whether the Rovartal combination strategy impacts outcomes in high-risk patient populations, particularly those with hypercholesterolemia inadequately controlled by single therapy. Studies explored whether using Rovartal alongside another lipid-regulating agent, as opposed to Rovartal alone, affected lipid profile endpoints.

Efficacy Data from Key Trials

Clinical trials, including Phase III studies, primarily measured changes in lipid markers such as Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol (TC), and triglycerides. The research was designed to measure observed changes in these markers over specific treatment periods.

Phase III Trial Findings:
- Primary research measured LDL-C levels for the drug group and the placebo group over short-term periods (e.g., 8 to 12 weeks).
- Studies also included assessment of patient-reported outcomes, such as the time to onset of an observable effect or changes in reported symptoms.

How Studies Investigated Drug Action

Mechanism of Action Studies: Research focused on Rovartal's function as a competitive inhibitor of HMG-CoA reductase, an enzyme key to cholesterol synthesis in the liver. Studies measured the drug’s potential interaction with specific cell receptors and associated cellular biomarkers.

Safety and Tolerability Profile

Research documented that Rovartal was associated with temporary elevation of liver function markers (AST/ALT), and this was monitored in trials. Most reported adverse events were classified as mild-to-moderate and commonly included headache, nausea, and general muscle pain (myalgia). Safety evaluations also tracked the frequency and severity of adverse events in both active drug and comparator arms.

Emerging Research Directions

Newer research has begun to explore research questions for the use of Rovartal in individuals with specific inflammatory conditions or cardiovascular risks beyond its primary indication. These are typically early-stage investigations (Phase II) or retrospective studies, and the data remains limited.

Frequently Asked Questions (FAQ)

Common questions about Rovartal (FAQ)

Q: What should I do if I miss a dose of Rovartal?

If a dose is forgotten, official guidelines state that a patient should not take an extra dose to compensate for the missed one. Treatment should instead resume with the next regularly scheduled dose. This guidance is provided to help avoid taking more than the prescribed amount.

Q: Does Rovartal interact with blood thinners like Warfarin?

Yes, official documents indicate that rosuvastatin can affect the action of Coumarin Anticoagulants, such as Warfarin. The combination may prolong the International Normalized Ratio (INR), a measure of clotting time. Monitoring of the INR is generally required by a healthcare professional when these medications are co-administered.

Q: Can children take Rovartal?

According to official product information, Rovartal is approved for use in certain children with high cholesterol conditions, such as Familial Hypercholesterolemia (FH). Indications generally apply to children aged 8 or older, depending on the specific condition. A healthcare professional determines eligibility based on the child's specific condition and age.

Q: How should I store Rovartal tablets?

Official information advises storing Rovartal at controlled room temperature, which is usually between 15 C and 30 C (59 F and 86 F). The tablets should be kept in a closed container and must be protected from moisture and heat to ensure their stability.

Q: Is Rovartal a high-intensity statin?

Yes, Rovartal (rosuvastatin) at doses of 20 mg and 40 mg is classified in clinical guidelines as a high-intensity statin. This means it is expected to achieve a significant reduction in Low-Density Lipoprotein Cholesterol (LDL-C). Lower doses are typically classified as moderate-intensity.

Q: What happens if I accidentally take two doses of Rovartal?

If there is suspicion of an overdose, a healthcare professional should be contacted promptly. The official prescribing information notes that there is no specific treatment for an overdose beyond general supportive care. It also states that the medicine cannot be removed from the body through procedures like hemodialysis.

Q: Can I stop taking Rovartal once my cholesterol is normal?

Regulatory guidance and official drug information advise patients not to stop taking Rovartal without first consulting a healthcare provider. The medication is typically part of a long-term plan to manage cholesterol levels and support overall cardiovascular risk reduction.

Q: What is the average half-life of Rovartal?

Official pharmacokinetic data for Rovartal (rosuvastatin) reports an elimination half-life of approximately 19 hours. The half-life is the time it takes for half of the drug's concentration to be eliminated from the body.

How should Rovartal be stored and disposed of?

How to Store and Dispose of Rovartal?

The official storage and disposal requirements for Rovartal (Rosuvastatin Calcium) are defined to ensure product stability and safety, as documented in regulatory labeling.

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, between 15 C and 30 C.
Protection	Keep in a closed, dry container, protected from moisture, heat, and direct light.
Safety	Must be kept out of the reach of children.

Disposal Instructions

Outdated or unused Rovartal tablets must not be kept. Regulatory guidance requires that disposal must follow appropriate local pharmaceutical waste procedures. Patients should consult a healthcare professional regarding specific instructions for discarding the medicine and should not discard it through household trash or wastewater unless explicitly advised.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.